Cargando…
Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open‐Label, Phase I Trial (JVDF)
LESSONS LEARNED. Ramucirumab plus pembrolizumab revealed no unexpected safety findings in patients with advanced or metastatic biliary tract cancer, which is consistent with reports of other tumor cohorts within this phase Ia/b trial. Ramucirumab plus pembrolizumab did not demonstrate an improvement...
Autores principales: | Arkenau, Hendrik‐Tobias, Martin‐Liberal, Juan, Calvo, Emiliano, Penel, Nicolas, Krebs, Matthew G., Herbst, Roy S., Walgren, Richard A., Widau, Ryan C., Mi, Gu, Jin, Jin, Ferry, David, Chau, Ian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AlphaMed Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292555/ https://www.ncbi.nlm.nih.gov/pubmed/29853658 http://dx.doi.org/10.1634/theoncologist.2018-0044 |
Ejemplares similares
-
Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial
por: Chau, Ian, et al.
Publicado: (2020) -
Safety and Preliminary Efficacy of Ramucirumab in Combination with FOLFOX4 in Patients with Advanced Hepatocellular Carcinoma: A Nonrandomized, Open‐Label, Phase Ib Study
por: Lin, Chia‐Chi, et al.
Publicado: (2020) -
Phase I Dose‐Escalation Study of Ramucirumab in Chinese Patients with Advanced Solid Tumors
por: Cao, Junning, et al.
Publicado: (2017) -
Electrocardiographic Characterization of Ramucirumab on the Corrected QT
Interval in a Phase II Study of Patients With Advanced Solid Tumors
por: Olszanski, Anthony J., et al.
Publicado: (2016) -
A Prospective Trial Evaluating the Safety of a Shortened Infusion of Ramucirumab in Patients with Gastrointestinal Cancer
por: Hashimoto, Naoya, et al.
Publicado: (2018)